Alzheimer ‘s disease
Accelerating Alzheimer’s Research: The Alzheimer’s Drug Discovery Foundation
Alzheimer’s disease, drug discovery, research funding, venture philanthropy, cognitive aging, dementia treatments
Axsome to Pursue FDA Approval for Alzheimer’s Agitation Treatment Despite Mixed Trial Results
Axsome Therapeutics, Alzheimer’s disease agitation, FDA approval, mixed trial data, AXS-05
Bristol Myers Squibb Partners with BioArctic in $100M Alzheimer’s Deal
Bristol Myers Squibb, BioArctic, Leqembi, Alzheimer’s disease, collaboration, $100M upfront payment
Bristol Myers Squibb Invests $100M in BioArctic for Next-Generation Alzheimer’s Therapies
Alzheimer’s disease, Bristol Myers Squibb, BioArctic, Leqembi, preclinical antibodies, BAN1503, BAN2803
GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments
Muna Therapeutics, GSK, Alzheimer’s disease, neurodegenerative diseases, spatial transcriptomics, MiND-MAP platform, drug discovery, therapeutic targets.
GSK Partners with Muna Therapeutics to Advance Alzheimer’s Treatment Research
GSK, Muna Therapeutics, Alzheimer’s disease, neurodegenerative diseases, drug research, genetic code analysis, neuroscience, collaboration.
Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial
Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry
Cassava Sciences’ Alzheimer’s Drug Fails in Clinical Trial, Stock Plummets
Cassava Sciences, Alzheimer’s disease, clinical trial failure, ReThink-ALZ study, stock decline
EMA Reverses Decision, Recommends Approval of Lecanemab (Leqembi) for Early Alzheimer’s Disease in Specific Patient Group
Lecanemab, Leqembi, Alzheimer’s disease, EMA, CHMP, early Alzheimer’s disease, ApoE ε4, amyloid-beta monoclonal antibody
Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges
Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry